Patients today are seeking more than temporary aesthetic solutions; They’re looking for safe*, clinically proven treatments that deliver lasting rejuvenation and natural-looking outcomes. Ellansé enables practitioners to meet this demand with a biostimulatory approach that supports long-term collagen regeneration and patient satisfaction. *Data on file"
GET IN TOUCHELLANSÉ is a dual-action collagen biostimulator designed to support facial structure immediately while stimulating the body’s natural collagen production over time. As the face ages, changes occur across multiple layers — including the skin, fat compartments, ligaments and bone support. This can lead to loss of definition, deeper folds, skin laxity and a tired appearance. ELLANSÉ supports a structure-first approach, helping restore contour, projection and support while improving skin quality over time.
TALK TO OUR EXPERTSHow ELLANSÉ works ELLANSÉ contains polycaprolactone microspheres suspended in a carboxymethyl cellulose gel carrier. The gel carrier provides immediate structural correction, while the PCL microspheres act as a scaffold to stimulate new collagen formation. As the carrier gradually absorbs, the collagen response helps maintain support and improve tissue quality. This creates a treatment effect that evolves — moving from instant correction to progressive, natural-looking rejuvenation.
SPEAK WITH OUR VIRTUAL ACCOUNT MANAGERSELLANSÉ provides immediate correction like a filler, but it is also a collagen biostimulator. It supports structure while stimulating collagen production over time.
Some improvement may be visible immediately after treatment, with collagen-led improvements developing gradually over time.
Results may last up to 18–24 months, depending on the product used, treatment area and individual patient factors
Suitability depends on anatomy, ageing pattern, goals and medical history. A consultation with a trained healthcare professional is essential.
INDICATION:
The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.
0344 
W321.02. Manufactured by: AQTIS Medical BV, Yalelaan 44, 3584 CM Utrecht, The Netherlands.
CorWeb.03
Ellansé Summary of Safety and Clinical Performance
INDICATION:
The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.
Important Safety Considerations:
Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction (redness, swelling, rash, oedema, erythema, lumps/nodules etc.), pain (which may be temporary or persistent in nature), transient haematoma or bruising.
Other potential adverse events include
- Injection related reactions, include itching, discoloration or tenderness may occur at the site of the injection. These usually resolve spontaneously within several days after the injection.
- As with any implant material possible adverse reactions that may occur include, but are not limited to the following: hypersensitivity, allergic reactions, inflammation, infection, fistula formation, haematoma, seroma, extrusion, induration formation, inadequate healing, skin discoloration, oedema, contusions/bruises, ecchymosis, inadequate or excessive augmentation, loss of correction, interference with local circulation if injected into a blood vessel resulting in vessel laceration, occlusion, embolism, infarction, and abscess at implant site which may result in induration and/or scar formation.
- Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral haemorrhage, leading to stroke, skin necrosis, damage to underlying facial structures, nausea and vomiting, lack of ocular movement, significant skin changes, ptosis, exotropia and neurological complications.
- Adverse events, other than mentioned above, could occur as can be with any medical intervention.
All (potential) adverse side effects and incidents should be reported immediately to the Sinclair Pharma Corporate Safety Group: quality@sinclairpharma.com
